Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2021 / Article
Special Issue

Oxidative Stress and Skin Health

View this Special Issue

Review Article | Open Access

Volume 2021 |Article ID 6652086 | https://doi.org/10.1155/2021/6652086

Qing Xiao, Lidan Xiong, Jie Tang, Li Li, Li Li, "Hydrogen Sulfide in Skin Diseases: A Novel Mediator and Therapeutic Target", Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6652086, 11 pages, 2021. https://doi.org/10.1155/2021/6652086

Hydrogen Sulfide in Skin Diseases: A Novel Mediator and Therapeutic Target

Academic Editor: Bonggi Lee
Received11 Jan 2021
Revised25 Mar 2021
Accepted07 Apr 2021
Published20 Apr 2021


Together with nitric oxide (NO) and carbon monoxide (CO), hydrogen sulfide (H2S) is now recognized as a vital gaseous transmitter. The ubiquitous distributions of H2S-producing enzymes and potent chemical reactivities of H2S in biological systems make H2S unique in its ability to regulate cellular and organ functions in both health and disease. Acting as an antioxidant, H2S can combat oxidative species such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) and protect the skin from oxidative stress. The aberrant metabolism of H2S is involved in the pathogenesis of several skin diseases, such as vascular disorders, psoriasis, ulcers, pigment disorders, and melanoma. Furthermore, H2S donors and some H2S hybrids have been evaluated in many experimental models of human disease and have shown promising therapeutic results. In this review, we discuss recent advances in understanding H2S and its antioxidant effects on skin pathology, the roles of altered H2S metabolism in skin disorders, and the potential value of H2S as a therapeutic intervention in skin diseases.

1. Introduction

The gasotransmitter hydrogen sulfide (H2S), recognized as the third gaseous signalling molecule along with nitric oxide (NO) and carbon monoxide (CO), is produced enzymatically in mammals under physiological conditions [1]. H2S was identified as a toxic gas pollutant with an odour of rotten eggs in the 18th century [2]. In 1996, Abe and Jincun reported the role of endogenous H2S in neuroregulation, which ushered in a new era of H2S and revealed its biological and pharmacological functions [3]. Later, a number of important biological effects of H2S were reported, including its vasorelaxation, antiapoptotic, anti-inflammatory, and antioxidative stress effects [36]. Emerging evidence has shown that endogenous H2S exhibits important functions by regulating multiple biological processes, particularly in the skin. Pathophysiological abnormalities related to altered H2S metabolism and function have been demonstrated in various dermatoses, such as psoriasis, vitiligo, and even melanoma [711]. In this review, we summarize the latest research progress on H2S-mediated effects, focusing on the most recent results and mechanism of the antioxidant effect of H2S in various skin diseases, to provide new insights into further exploration of its therapeutic targets.

2. Production and Metabolism of H2S in the Skin

2.1. Production of H2S

H2S can be produced by nonenzymatic and enzymatic pathways in mammalian organisms. Nonenzymatic processes are primarily produced by the decomposition of an inorganic substance, which contributes a little to the amount of H2S production. The main generation of H2S in cutaneous tissue mostly depends on enzymatic routes using L-cysteine and homocysteine by two pyridoxal-5-phosphate-dependent enzymes, cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE). The pyridoxal-5-phosphate-independent enzyme, 3-mercaptopyruvate sulfurtransferase (3-MST), displays enzymatic activity at a pH of 7.4, generating H2S from 3-mercaptopyruvate, which is produced by cysteine aminotransferase (CAT) in mitochondria [1214] (Figure 1).

The structure of the skin is shown in Figure 2. Skin has two main layers. The uppermost one is the epidermis, which is divided into five layers of cells made mostly out of keratinocytes, along with melanocytes, Merkel cells, and Langerhans cells. The dermis is the second one, a subjacent fibrous-collagenous-elastic tissue that hosts vessels, nerves, and sensory receptors. The subcutaneous tissue hypodermis is the deepest layer [15]. However, the precise localization of the H2S-generating enzymes in the different cell types of the skin has not yet been completely determined. Only a few reports revealed that gene expression for the H2S-producing enzymes occurs in normal human epidermal melanocytes and keratinocytes, which are located in the epidermis (rectangular area in Figure 2) [10, 16]. An immunohistochemical (IHC) analysis from human samples showed that CSE, CBS, and 3-MST express in normal human epidermal melanocytes, and all the dysplastic nevi were positive for CSE, negative for CBS, and variable for 3-MST [10]. CSE and 3-MST also express in the cutaneous circulation to regulate vasodilatation in humans [17, 18].

Consequently, H2S is currently accepted to present and exert various effects in skin, but the exact mechanism of H2S production in different cell types of the skin remains to be elucidated.

2.2. Metabolism of H2S

After its enzymatic synthesis, H2S can be either directly released or stored and liberated afterward, which maintains the proper physiological balance of its metabolism. Two forms of sulfur stores have been identified: bound sulfane sulfur and acid-labile sulfur [13, 19].

The exact details of H2S metabolism in the skin have not yet been elucidated. The main pathway of H2S catabolism is thought to occur in mitochondria by oxidation to thiosulfate and sulfate, excretion from the lung or kidney, and methylation via rhodanese and thiol methyltransferase in the cytosol [2022]. Meanwhile, H2S can interact with methemoglobin to form sulfhemoglobin, a possible biomarker of plasma H2S [23].

3. The Role of H2S in Skin Pathophysiology

Recently, an increasing amount of evidence has illustrated the essential roles of H2S in vasodilatation [17], wound healing [24], inflammation [16], antioxidation [8], and the regulation of cancer cells [9, 10, 25] in the skin (Figure 3).

3.1. H2S in Vascular Disorders

In the study of vascular signalling mechanisms in healthy and sick adults, the skin is a representative and accessible regional vascular bed that modulates vascular function [2628]. Deficits in cutaneous vascular function are highly associated with and predictive of vascular dysfunction in the coronary and renal circulation [29, 30].

CSE and 3-MST have been suggested to be expressed in the human microvasculature [17]. One recent study indicated that NaHS and Na2S may result in a significant dose-dependent increase in vasodilatation in the cutaneous circulation through tetraethylammonium-sensitive calcium-dependent potassium channels and functionally interact with both the COX and NO vasodilatory signalling pathways. Furthermore, as an endothelium-derived hyperpolarizing factor, H2S can also cause local thermal hyperaemia and reflex vasodilatation in cutaneous blood flow [17]. In the past, these functions were thought to be mediated by only endothelial NO synthase and epoxyeicosatrienoic acid-dependent mechanisms [31, 32].

Emerging evidence suggests that H2S is a physiologic vasodilator and regulator of blood pressure in many other organs and tissues. Rodent experiments showed that knockdown of CSE or treatment with the CSE inhibitor D,L-propargylglycine resulted in marked hypertension [3336]. In addition, H2S could protect against ischaemia/reperfusion (I/R) injury in the heart, liver, kidney, brain, intestine, stomach, hind limb, lung, and retina [37]. Therefore, targeting H2S or its donors might become a novel preventive and therapeutic strategy for the regulation of multiple vascular pathologies.

3.2. H2S in Inflammatory Disorders

The physical anti-inflammatory role of H2S has attracted extensive attention. Numerous studies have shown that endogenous and exogenous H2S play a critical role in the resolution of inflammation [38]. Additionally, psoriasis is a common T-cell-chronic inflammatory skin disease characterised by red, thickened plaques with overlying silver-white scales. According to Alshorafa et al., the serum levels of TNF-α, IL-6, and IL-8 in patients with psoriasis were higher than those in a healthy control group, and the level of H2S was lower than that in the healthy control group. Administration of HaCaT cells with exogenous H2S largely inhibited the TNF-α-mediated upregulation of NO, IL-6, and IL-8 in a dose-dependent manner by suppressing activation of the p38, MAPK, ERK, and NF-κB pathways [7].

Moreover, hypoxia of the skin is a common physiopathological characteristic of various skin diseases, such as diabetic ulcers [39, 40], pressure ulcers [41], and varicose ulcers [42], in which inflammation and oxidative stress injury are closely related. Yang et al. used cobalt chloride (CoCl2) as a hypoxia-mimicking agent to treat human skin keratinocytes (HaCaT cells) and demonstrated that 100-800 μM NaHS administration for 30 minutes could confer a cytoprotective effect against chemical hypoxia-induced cytotoxicity and inflammation through inhibiting the reactive oxygen species- (ROS-) activated NF-κB/COX-2 signalling pathway in HaCaT cells [43].

Likewise, evidence suggests that both CSE and CBS alleviate inflammation in the skin [16]. The expression of these enzymes was upregulated in human keratinocytes treated with formaldehyde at subcytotoxic concentrations, and the H2S produced could, in turn, inhibit an increase in proinflammatory factors (such as MMP-1, PGE2, and IL-8), which are involved in early proinflammatory processes. In addition, in mice with the cutaneous Arthus reaction, exposure to NaHS decreased the number of neutrophils recruited to skin lesions and attenuated TNF-α and IFN-γ expression in the inflammatory reaction [44].

3.3. H2S in Wound Healing

The proliferation and differentiation of the epidermis are indispensable processes in wound repair that are often dysregulated under pathologic conditions, such as those in psoriasis, epidermal cancers, atopic dermatitis (AD), and delayed wound healing [45, 46]. The proliferation and differentiation of human keratinocytes were found to be promoted by exogenous H2S in a dose-dependent manner by autophagy regulation [24]. Endogenous overexpression of CSE or the addition of exogenous NaHS at increasing concentrations (0-100 μM) and for increasing stimulation times (0-6 d) could also increase cell proliferation in primary human epidermal melanocytes [8].

Endogenous H2S has been demonstrated to promote wound healing. Researchers found that CSE expression and the H2S content are decreased in diabetic foot ulcers and the granulation tissues of wounds [47, 48]. The wound healing process was shown to be significantly delayed in CSE−/− mice compared with CSE+/+ mice, and blockade of CBS had the same effects, decreasing the wound closure rate and cell migration [49, 50]. In contrast, intraperitoneal treatment with NaHS and 4-hydroxythiobenzamide dramatically improved wound healing through the activation of angiopoietin-1 and restoration of endothelial progenitor cell functions in type 2 diabetic db/db mice [47]. To better understand the underlying mechanism of this effect, a recent study showed that downregulation of neutrophil extracellular trap (NET) release and blockade of ROS-induced MAPK ERK1/2 and p38 activation played an important role in the improved diabetic wound healing caused by Na2S [51]. Additionally, H2S could promote ischaemic diabetic wound healing via increasing the production of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), hypoxia inducible factor-1α (HIF-1α), and endothelial nitric oxide synthase (eNOS) in type 2 diabetic db/db mice [52]. Topical treatment with a 2% NaHS-containing ointment also accelerated wound healing by modulating angiogenesis in the granulation tissues via augmented VEGF levels in rats with streptozotocin-induced diabetes [53].

Furthermore, Zhao et al. suggested that improved wound healing by NaHS treatment in diabetic ob/ob mice was associated with reduced neutrophil and macrophage infiltration; decreased production of TNF-α, IL-6, and MMP-9; and increased collagen deposition in granulation tissues [48]. Thus, the identification of H2S as a small-molecule stimulus for cell proliferation and wound healing provides essential information for understanding epidermal repair and disorders and offers potential targets for future therapy.

3.4. H2S in Pigment Skin Disorders and Fibrotic Disease

Accumulating evidence suggests that H2S may confer protective effects against various types of stimuli-triggered damage in different organs, such as the skin, heart, and brain [8, 54, 55]. One of the dominant mechanisms of H2S protection is its antioxidant effect, which is exerted not only by increased reduced glutathione (GSH) but also the direct scavenging of superoxide anion (O2-), hydrogen peroxide (H2O2) [56], and peroxynitrite (ONOO-) [57] to combat oxidative stress.

A recent study showed that 10-100 μM NaHS and the overexpression of CSE could promote cell proliferation and melanin synthesis by increasing the production of melanogenic enzymes (MITF, TYR, and TRP-1) in primary human epidermal melanocytes [8]. Melanocyte regeneration and melanin synthesis play important biological roles in pigment skin disorders and processes such as vitiligo, hair greying, and albinism [58, 59]. Synthesized and deposited in melanosomes, melanin can be transported to nearby keratinocytes to induce pigmentation, protecting the epidermis and underlying fibroblasts in the dermis from ultraviolet damage, which results in photoaging, oxidative stress, and even skin cancer [60, 61]. Therefore, pharmacologic regulation of H2S may be a novel strategy for skin disorders caused by the loss of melanocytes and dysregulation of oxidative stress.

Excessive oxidative stress is one of the dominant causes of wound healing impairment [62]. ROS arising from inflammatory cells activates various molecular signalling pathways to block angiogenesis or cytokine secretion to delay wound healing. The antioxidant and cytoprotective effects of H2S are also observed in the skin wound healing process [63, 64]. For example, attenuated ROS and increased VEGF expression are the main reasons for the accelerated wound healing and improved blood flow observed after pretreatment of wounds with NaHS after an operation. NaHS also promotes skin fibroblast and keratinocyte migration by alleviating ROS and increasing mitochondrial membrane potential [65]. In addition, Na2S could improve diabetic wound healing by downregulating NET release and suppressing ROS-induced MAPK ERK1/2 and p38 activation [51]. In a rodent experiment, the production of endogenous H2S, CBS, and CSE declined largely in the early stage after wounding, but intraperitoneal injection of GYY4137 (an exogenous H2S donor) at 50 mg·kg-1·day-1 significantly inhibited the activation of the M1 phenotype induced by mucosal wound inflammation and accelerated wound healing by downregulating the NF-κB signalling pathway [66]. Taken together, these findings suggest that exogenous H2S supplementation and endogenous H2S overexpression are potential strategies to combat oxidative stress and control inflammation to promote skin wound healing.

In addition, the physical effect of H2S against oxidative stress and inflammation in the development of fibrosis has attracted significant attention [67]. Abnormal H2S metabolism is associated with the pathogenesis of fibrosis, causing damage to the structure and function of tissues and organs. Several in vivo and in vitro studies have shown that both endogenous H2S levels and the expression of H2S-related enzymes in plasma are significantly decreased in fibrotic diseases, but supplementation with exogenous H2S could alleviate the severity of fibrosis in different experimental animal models [68, 69]. The cytoprotective role of H2S in fibrosis is mainly attributed to its antioxidant, antiapoptotic, anti-inflammatory, and fibroblast-inhibitory activities [7073]. H2S could restore a normal morphologic phenotype in Werner syndrome fibroblasts by attenuating oxidative damage and modulating the mTOR pathway [74]. Wang et al. demonstrated the beneficial effects of H2S on systemic sclerosis-associated skin and lung fibrosis. Intraperitoneal injection of NaHS markedly reduced the expression of fibrotic biomarkers such as α-smooth muscle actin, collagen-I, collagen-III, fibronectin, transforming growth factor-β1, Smad2/3 phosphorylation, and monocyte chemoattractant protein-1 in the lung in a mouse model, suggesting that H2S may be a potential therapy against systemic sclerosis-related organ fibrosis in the clinic [75].

3.5. H2S in Skin Cancers

H2S has a crucial role in multiple types of cancers, including human melanoma [10, 25, 76]. Generally, endogenous H2S or a relatively low concentration of exogenous H2S might promote or maintain cancer cell growth over a relatively short duration, while overexpression of H2S-generating enzymes or exposure to a relatively high level of H2S donor may have an anticancer effect over a relatively long duration [25].

Immunohistochemical (IHC) analysis of over 100 human subjects showed that the CSE level was increased from the transition from nevus to primary melanoma, decreased in metastatic lesions, and almost absent in lymph node metastases, and the expression of CSE and 3-MST was significantly higher than that in normal human epidermal melanocytes [10]. Overexpression of CSE led to spontaneous apoptosis in human melanoma cells by decreasing the levels of antiapoptotic proteins and suppressing the activation of NF-κB. It was also reported that an exogenous H2S donor—DATS, an active component in garlic oil—at 100 μM inhibited the proliferation of A375 human melanoma cells by downregulating the Akt and ERK pathways. Further treatment with the CSE substrate L-cysteine at 600 mg·kg−1 or 50 mg·kg−1 DATS significantly inhibited tumour growth in mice subcutaneously injected with B16-F10 cells by 67% compared with that in the control group [10]. A recent study also found that treatment of the A375 and SK-MEL-28 human melanoma cell lines with 2 mM NaHS, a donor to H2S gas, for 24 hours attenuated cell proliferation and migration and arrested the cell cycle but induced cell autophagy. Suppression of autophagy by ATG7 shRNA enhanced H2S-regulated cell apoptosis but had no synergistic effect on cell proliferation, migration, or division. Furthermore, NaHS treatment could decrease the protein expression of p-PI3K, p-Akt, and mTOR, while insulin-like growth factor-1 (IGF-1), an activator of the PI3K/AKT/mTOR pathway, could partly reverse the changes in cellular behaviour caused by NaHS, which suggested that the inhibition of human melanoma cell development by exogenous H2S donors might be correlated with suppression of the PI3K/AKT/mTOR pathway [9]. Moreover, 25 μM DATS inhibited the growth of both human melanoma cells and basal cell carcinoma cells by upregulating cytosolic Ca2+ mobilization and intracellular ROS production and decreasing the activities and protein expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 without a significant effect on normal keratinocyte HaCaT cell growth [77]. Specifically, the inhibitory effect of DATS on invasion and metastasis in A375 cells was found to correlate with decreased levels of several integrin subunits and focal adhesion kinase (FAK) [78]. These results suggest that the antimetastatic potential of DATS for human melanoma cells might be due to disruption of the integrin/FAK signalling pathway.

Another H2S-releasing naproxen derivative, naproxen-4-hydroxybenzodithioate, at 10 and 30 μM was reported to induce caspase 3-mediated apoptosis and suppress human melanoma cell proliferation, migration, invasion, and colony formation in vitro [79].

Nevertheless, many studies have shown that in primary melanoma, the expression of CSE is usually increased, and the overexpression of CSE in cancer cells has a tumour-promoting effect; furthermore, blockade of CSE enzymatic activity reduced proliferation rates in human melanoma cells [80]. Therefore, to achieve anticancer efficacy, further research is needed to explore a reasonable strategy for H2S drug application, since different types of cancer cells exhibit distinct drug susceptibilities and physiological traits. Figure 4 shows the roles of H2S in skin cancers.

According to the abovementioned findings, the regulatory effects of different H2S donors on various skin cell types/tissues are summarized in Table 1.

Cells/tissuesTargetH2S donor(s)EffectsRef.

Cutaneous vesselsCOX and NO vasodilatory signalling pathwayNaHS and Na2SVasodilatation[17]
HaCaT cellsp38, MAPK, ERK, and NF-κB pathwaysNaHSInhibit the TNF-α-mediated upregulation of NO, IL-6, and IL-8[7]
HaCaT cellsROS-activated NF-κB/COX-2 signalling pathwayNaHSInhibit chemical hypoxia-induced cytotoxicity and inflammation[43]
HaCaT cellsAutophagyNaHSPromote proliferation and differentiation[25]
Endothelial progenitor cellAngiopoietin-1NaHS and 4-hydroxythiobenzamideImprove diabetic wound healing[47]
Mouse skinNETs and ROS-induced MAPK, ERK1/2, and p38 signaling pathwaysNa2SImprove diabetic wound healing[51]
Ischemic mouse adductor muscleVEGF, EGF, PDGF, HIF-1α, and eNOSNa2SPromote ischemic diabetic wound healing[52]
Granulation tissuesVEGFNaHS-containing ointmentAccelerate diabetic wound healing[53]
Primary human epidermal melanocytesMelanogenic enzymes (MITF, TYR, and TRP-1)NaHSPromote cell proliferation and melanin synthesis[8]
Skin fibroblasts and keratinocytesROS and mitochondrial membrane potentialNaHSAccelerate wound healing and improve blood flow[65]
Oral mucosa, peritoneal macrophages, and RAW264.7 cellsNF-κB signalling pathwayGYY4137Inhibit mucosal wound inflammation and accelerate wound healing[66]
Skin fibroblast cell lines (AG11395 and AG12795)mTOR pathwayNaHSRestore a normal morphologic phenotype[74]
Mouse skin and lungα-Smooth muscle actin, collagen-I, collagen-III, fibronectin, TGF-β1, Smad2/3NaHSAlleviate the severity of systemic sclerosis-associated skin and lung fibrosis[75]
A375 human melanomaNF-κB, AKT/ERK pathwaysDATSInhibit melanoma proliferation, invasion, and metastasis[10]
B16- F10 cellsAKT/ERK pathwayCSE substrate L-cysteine or DATSInhibit tumour growth[10]
A375 and SK-MEL-28 human melanomaPI3K/AKT/mTOR pathwayNaHSInhibit tumour growth, migration, and cell cycle[9]
A375 and basal cell carcinoma cellsCytosolic Ca2+, ROS, and mitochondrial membrane potentialDATSInhibit tumour growth[77]
A375 human melanomaIntegrin/FAK pathwayDATSInhibit cell migration and invasion[78]
A375 human melanomaCaspase 3Naproxen-HBTASuppress human melanoma cell proliferation, migration, invasion, and colony formation[79]

4. Therapeutic Potential of H2S in Skin Diseases

In ancient times, our ancestors discovered the beneficial properties of bathing in thermal spring water, and this therapy remains a popular form of treatment for chronic skin and rheumatologic diseases today. The waters used to treat skin conditions have different physical and chemical compositions but are generally rich in sulfur, H2S, sulfates, and other ions [81, 82]. The activity of sulfur in the skin seems to be related mainly to its interaction with cysteine and its catabolites [83].

Bathing in sulfur-rich spring water can treat many immune-mediated skin diseases, such as psoriasis and AD. Due to the sulfur and H2S in thermal water, this therapy can decrease scales, pruritus, and inflammation in patients with psoriasis and exert beneficial anti-inflammatory, keratoplastic, and antipruriginous effects [84]. The use of sulfur water has also been proposed to relieve AD, leg ulcers, acne, and hidradenitis suppurativa lesions because sulfur can interact with ROS in the deeper epidermis, producing sulfur and H2S, which may be transformed into pentathionic acid; this pentathionic acid may be the source of the antibacterial and antifungal properties of thermal springs [8587]. Moreover, sulfur water is therapeutic in acne patients due to its keratolytic effect, which results in peeling [88]. Therefore, bathing in sulfur-containing hot springs acts as an important alternative dermatological therapy.

Multiple recent in vivo and in vitro experiments have shed light on the biological and pharmacological roles of H2S under a variety of physiological and pathological conditions. An increasing number of therapeutic applications of H2S in skin diseases have also been revealed. As mentioned above, sulfide salts, including NaHS and Na2S, are the most common class of H2S donors applied in biological studies, providing direct, instantaneous access to the physiologically relevant forms of sulfide (H2S and HS) [89]. Diallyl disulfide (DADS) is the active compound from allicin, and GYY4137 is a water-soluble donor used as the “gold standard” H2S donor in a large number of experimental studies [90]. These H2S donors have been or are currently under evaluation in clinical trials. A few notable examples include the naproxen-based H2S donors ATB-346 and naproxen-HBTA, which have been reported to exert anti-inflammatory and anticancer effects [91]. Researchers reported that 100 μM ATB-346 and 30 μM naproxen-HBTA could inhibit human melanoma cell proliferation, migration, invasion, and colony formation, with the possible mechanisms including inhibition of prosurvival pathways associated with NF-κB and Akt activation.

Furthermore, polycaprolactone (PCL) containing jk1 was electrospun to prepare a pH-controlled H2S donor, generating a kind of nanofibre with a H2S-release function. PCL-jk1 could significantly promote wound repair and regeneration compared to that in a control group, which may have been due to the release of H2S, confirming the important role of H2S function in physiological protection of wounds [92]. In addition, Lin et al. produced an H2S-releasing depot formulation termed “NaHS@MPs” to treat diabetic wounds. Topical NaHS@MPs treatment of the wounds of diabetic db/db mice increased the proliferation and migration of epidermal keratinocytes, as well as angiogenesis, by inducing sustained phosphorylation of ERK1/2 and p38 and thus improved the healing of full-thickness wounds [93].

5. Conclusions

H2S, the third kind of gaseous signalling molecule, plays important roles in physiological regulatory processes in the skin (Table 1) and joins NO and CO in the group of signalling agents termed “gasotransmitters.” CSE, CBS, and 3-MST are three key H2S-producing enzymes that can be detected in the epidermis. Altered expression levels of these enzymes or H2S levels are usually associated with various skin diseases, including psoriasis, vitiligo, fibrosis, delayed wound healing, and even melanoma. Thus, CSE, CBS, and 3-MST might be biomarkers and novel molecular targets for dermatological diagnostics and treatment.

It is simultaneously becoming increasingly obvious that oxidative stress alters a number of redox-sensitive signalling pathways in different skin types, contributing to skin ageing and numerous cutaneous diseases, including skin cancers [94]. H2S, as an antioxidant, can protect cells from oxidative damage by decreasing the production of intracellular ROS [95]. Thus, the application of H2S might serve as an effective and easy method to improve these skin conditions. In addition, remarkable progress has been made in the fields of H2S donor chemistry and biomaterials in a short period of time since the therapeutic potential of H2S was discovered. Therefore, filling the knowledge gaps regarding the precise metabolic mechanism behind the role of H2S in skin disorders and appropriate treatment with H2S are key issues to be addressed, which may facilitate promising strategies for the further clinical application of H2S in dermatology.


H2S:Hydrogen sulfide
NaHS:Sodium hydrosulfide
PI3K:Phosphatidylinositol 3-kinase
Akt:Protein kinase B
mTOR:Mammalian target of rapamycin
IGF-1:Insulin-like growth factor-1
NO:Nitric oxide
CO:Carbon monoxide
CSE:Cystathionine γ-lyase
CBS:Cystathionine β-synthase
3-MST:3-Mercaptopyruvate sulfurtransferase
NF-κB:Nuclear factor-κB
MAPK:Mitogen-activated protein kinase
ERK:Extracellular regulated protein kinase
NET:Neutrophil extracellular trap
ROS:Reactive oxygen species
VEGF:Vascular endothelial growth factor
EGF:Epidermal growth factor
PDGF:Platelet-derived growth factor
HIF-1α:Hypoxia inducible factor-1α
eNOS:Endothelial nitric oxide synthase
MITF:Microphthalmia-associated transcription factor
TRP-1:TYR-related protein 1
TGF-β1:Transforming growth factor-β1
CoCl2:Cobalt chloride
DATS:Diallyl trisulfide
GYY4137:Morpholin-4-ium-4-methoxyphenyl(morpholino) phosphinodithioate
O2-:Superoxide anion
H2O2:Hydrogen peroxide.

Data Availability

Data in this review can be found in the references part.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Qing Xiao organized, wrote, and prepared the manuscript. Lidan Xiong, Jie Tang, and Li Li contributed in writing and reviewing the major parts of the manuscript. All authors read and approved the final manuscript.


This work was supported by grants from Natural Science Foundation of China (Nos. 81673084) and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.


  1. K. Abe and H. Kimura, “The possible role of hydrogen sulfide as an endogenous neuromodulator,” The Journal of Neuroscience, vol. 16, no. 3, pp. 1066–1071, 1996. View at: Publisher Site | Google Scholar
  2. R. Wang, “Physiological implications of hydrogen sulfide: a whiff exploration that blossomed,” Physiological Reviews, vol. 92, no. 2, pp. 791–896, 2012. View at: Publisher Site | Google Scholar
  3. H. Kruszyna, R. Kruszyna, and R. P. Smith, “Cyanide and sulfide interact with nitrogenous compounds to influence the relaxation of various smooth muscles,” Proceedings of the Society for Experimental Biology and Medicine, vol. 179, no. 1, pp. 44–49, 1985. View at: Publisher Site | Google Scholar
  4. Q. Xiao, J. Ying, L. Xiang, and C. Zhang, “The biologic effect of hydrogen sulfide and its function in various diseases,” Medicine, vol. 97, no. 44, article e13065, 2018. View at: Publisher Site | Google Scholar
  5. E. Zaorska, L. Tomasova, D. Koszelewski, R. Ostaszewski, and M. Ufnal, “Hydrogen sulfide in pharmacotherapy, beyond the hydrogen sulfide-donors,” Biomolecules, vol. 10, no. 2, p. 323, 2020. View at: Publisher Site | Google Scholar
  6. D. Wu, W. Si, M. Wang, S. Lv, A. Ji, and Y. Li, “Hydrogen sulfide in cancer: friend or foe?” Nitric Oxide, vol. 50, pp. 38–45, 2015. View at: Publisher Site | Google Scholar
  7. A. K. Alshorafa, Q. Guo, F. Zeng et al., “Psoriasis is associated with low serum levels of hydrogen sulfide, a potential anti-inflammatory molecule,” The Tohoku Journal of Experimental Medicine, vol. 228, no. 4, pp. 325–332, 2012. View at: Publisher Site | Google Scholar
  8. J. Ying, Q. Wang, M. Jiang et al., “Hydrogen sulfide promotes cell proliferation and melanin synthesis in primary human epidermal melanocytes,” Skin Pharmacology and Physiology, vol. 33, no. 2, pp. 61–68, 2020. View at: Publisher Site | Google Scholar
  9. Q. Xiao, J. Ying, Z. Qiao et al., “Exogenous hydrogen sulfide inhibits human melanoma cell development via suppression of the PI3K/AKT/ mTOR pathway,” Journal of Dermatological Science, vol. 98, no. 1, pp. 26–34, 2020. View at: Publisher Site | Google Scholar
  10. E. Panza, P. de Cicco, C. Armogida et al., “Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression,” Pigment Cell & Melanoma Research, vol. 28, no. 1, pp. 61–72, 2015. View at: Publisher Site | Google Scholar
  11. M. N. Hughes, M. N. Centelles, and K. P. Moore, “Making and working with hydrogen sulfide:,” Free Radical Biology & Medicine, vol. 47, no. 10, pp. 1346–1353, 2009. View at: Publisher Site | Google Scholar
  12. M. D. Hartle and M. D. Pluth, “A practical guide to working with H2S at the interface of chemistry and biology,” Chemical Society Reviews, vol. 45, no. 22, pp. 6108–6117, 2016. View at: Publisher Site | Google Scholar
  13. S. Singh, D. Padovani, R. A. Leslie, T. Chiku, and R. Banerjee, “Relative contributions of cystathionine β-synthase and γ-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions,” Journal of Biological Chemistry, vol. 284, no. 33, pp. 22457–22466, 2009. View at: Publisher Site | Google Scholar
  14. P. K. Yadav, K. Yamada, T. Chiku, M. Koutmos, and R. Banerjee, “Structure and kinetic analysis of H2S production by human mercaptopyruvate sulfurtransferase,” The Journal of Biological Chemistry, vol. 288, no. 27, pp. 20002–20013, 2013. View at: Publisher Site | Google Scholar
  15. O. Arda, N. Göksügür, and Y. Tüzün, “Basic histological structure and functions of facial skin,” Clinics in Dermatology, vol. 32, no. 1, pp. 3–13, 2014. View at: Publisher Site | Google Scholar
  16. E. Lee, H. J. Kim, M. Lee et al., “Cystathionine metabolic enzymes play a role in the inflammation resolution of human keratinocytes in response to sub-cytotoxic formaldehyde exposure,” Toxicology and Applied Pharmacology, vol. 310, pp. 185–194, 2016. View at: Publisher Site | Google Scholar
  17. J. L. Kutz, J. L. Greaney, L. Santhanam, and L. M. Alexander, “Evidence for a functional vasodilatatory role for hydrogen sulphide in the human cutaneous microvasculature,” The Journal of Physiology, vol. 593, no. 9, pp. 2121–2129, 2015. View at: Publisher Site | Google Scholar
  18. R. Hosoki, N. Matsuki, and H. Kimura, “The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide,” Biochemical and Biophysical Research Communications, vol. 237, no. 3, pp. 527–531, 1997. View at: Publisher Site | Google Scholar
  19. Y. Ogasawara, S. Isoda, and S. Tanabe, “Tissue and subcellular distribution of bound and acid-labile sulfur, and the enzymic capacity for sulfide production in the rat,” Biological & Pharmaceutical Bulletin, vol. 17, no. 12, pp. 1535–1542, 1994. View at: Publisher Site | Google Scholar
  20. A. Stein and S. M. Bailey, “Redox biology of hydrogen sulfide: implications for physiology, pathophysiology, and pharmacology,” Redox Biology, vol. 1, no. 1, pp. 32–39, 2013. View at: Publisher Site | Google Scholar
  21. O. Kabil and R. Banerjee, “Redox biochemistry of hydrogen sulfide,” The Journal of Biological Chemistry, vol. 285, no. 29, pp. 21903–21907, 2010. View at: Publisher Site | Google Scholar
  22. T. M. Hildebrandt and M. K. Grieshaber, “Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria,” FEBS Journal, vol. 275, no. 13, pp. 3352–3361, 2008. View at: Publisher Site | Google Scholar
  23. A. Saeedi, A. Najibi, and A. Mohammadi-Bardbori, “Effects of long-term exposure to hydrogen sulfide on human red blood cells,” The International Journal of Occupational and Environmental Medicine, vol. 6, no. 1, pp. 20–25, 2015. View at: Publisher Site | Google Scholar
  24. X. Xie, H. Dai, B. Zhuang, L. Chai, Y. Xie, and Y. Li, “Exogenous hydrogen sulfide promotes cell proliferation and differentiation by modulating autophagy in human keratinocytes,” Biochemical and Biophysical Research Communications, vol. 472, no. 3, pp. 437–443, 2016. View at: Publisher Site | Google Scholar
  25. M. R. Hellmich and C. Szabo, “Hydrogen sulfide and cancer,” Handbook of Experimental Pharmacology, vol. 230, pp. 233–241, 2015. View at: Publisher Site | Google Scholar
  26. C. J. Abularrage, A. N. Sidawy, G. Aidinian, N. Singh, J. M. Weiswasser, and S. Arora, “Evaluation of the microcirculation in vascular disease,” Journal of Vascular Surgery, vol. 42, no. 3, pp. 574–581, 2005. View at: Publisher Site | Google Scholar
  27. M. Rossi, A. Carpi, F. Galetta, F. Franzoni, and G. Santoro, “The investigation of skin blood flowmotion: a new approach to study the microcirculatory impairment in vascular diseases?” Biomedicine & Pharmacotherapy, vol. 60, no. 8, pp. 437–442, 2006. View at: Publisher Site | Google Scholar
  28. L. A. Holowatz, C. S. Thompson-Torgerson, and W. L. Kenney, “The human cutaneous circulation as a model of generalized microvascular function,” Journal of Applied Physiology, vol. 105, no. 1, pp. 370–372, 2008. View at: Publisher Site | Google Scholar
  29. F. Khan, D. Patterson, J. J. Belch, K. Hirata, and C. C. Lang, “Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography,” Clinical Science, vol. 115, no. 9, pp. 295–300, 2008. View at: Publisher Site | Google Scholar
  30. P. Coulon, J. Constans, and P. Gosse, “Impairment of skin blood flow during post-occlusive reactive hyperhemy assessed by laser Doppler flowmetry correlates with renal resistive index,” Journal of Human Hypertension, vol. 26, no. 1, pp. 56–63, 2012. View at: Publisher Site | Google Scholar
  31. R. S. Bruning, L. Santhanam, A. E. Stanhewicz et al., “Endothelial nitric oxide synthase mediates cutaneous vasodilation during local heating and is attenuated in middle-aged human skin,” Journal of Applied Physiology, vol. 112, no. 12, pp. 2019–2026, 2012. View at: Publisher Site | Google Scholar
  32. V. E. Brunt and C. T. Minson, “KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin,” The Journal of Physiology, vol. 590, no. 15, pp. 3523–3534, 2012. View at: Publisher Site | Google Scholar
  33. P. L. Huang, Z. H. Huang, H. Mashimo et al., “Hypertension in mice lacking the gene for endothelial nitric oxide synthase,” Nature, vol. 377, no. 6546, pp. 239–242, 1995. View at: Publisher Site | Google Scholar
  34. K. D. Lake-Bruse, F. M. Faraci, E. G. Shesely et al., “Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice,” American Journal of Physiology Heart & Circulatory Physiology, vol. 277, no. 2, pp. H770–H776, 1999. View at: Publisher Site | Google Scholar
  35. E. G. Shesel, “Elevated blood pressures in mice lacking endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences, vol. 93, no. 23, pp. 13176–13181, 1996. View at: Publisher Site | Google Scholar
  36. W. Zhao, J. F. Ndisang, R. Wang, and J. Can, “Modulation of endogenous production of H2S in rat tissues,” Canadian Journal of Physiology and Pharmacology, vol. 81, no. 9, pp. 848–853, 2003. View at: Publisher Site | Google Scholar
  37. D. Wu, J. Wang, H. Li, M. Xue, A. Ji, and Y. Li, “Role of hydrogen sulfide in ischemia-reperfusion injury,” Oxidative medicine and cellular longevity, vol. 2015, Article ID 186908, 16 pages, 2015. View at: Publisher Site | Google Scholar
  38. J. L. Wallace, J. G. P. Ferraz, and M. N. Muscara, “Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury,” Antioxidants & Redox Signaling, vol. 17, no. 1, pp. 58–67, 2012. View at: Publisher Site | Google Scholar
  39. L. S. Barcelos, C. Duplaa, N. Kränkel et al., “Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling,” Circulation Research, vol. 104, no. 9, pp. 1095–1102, 2009. View at: Publisher Site | Google Scholar
  40. E. B. Bolajoko, K. S. Mossanda, F. Adeniyi, O. Akinosun, A. Fasanmade, and M. Moropane, “Antioxidant and oxidative stress status in type 2 diabetes and diabetic foot ulcer,” South African Medical Journal, vol. 98, no. 8, pp. 614–617, 2008. View at: Google Scholar
  41. T. A. Mustoe, K. O’Shaughnessy, and O. Kloeters, “Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis,” Plastic and Reconstructive Surgery, vol. 117, pp. 35S–41S, 2006. View at: Publisher Site | Google Scholar
  42. M. K. Lazarides and A. D. Giannoukas, “The role of hemodynamic measurements in the management of venous and ischemic ulcers,” The International Journal of Lower Extremity Wounds, vol. 6, no. 4, pp. 254–261, 2007. View at: Publisher Site | Google Scholar
  43. C. Yang, Z. Yang, M. Zhang et al., “Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in HaCaT cells through inhibition of ROS/NF-κB/COX-2 pathway,” PLoS One, vol. 6, no. 7, article e21971, 2011. View at: Publisher Site | Google Scholar
  44. K. Shimizu, F. Ogawa, T. Hara et al., “Exogenous application of hydrogen sulfide donor attenuates inflammatory reactions through the L-selectin-involved pathway in the cutaneous reverse passive Arthus reaction,” Journal of Leukocyte Biology s, vol. 93, no. 4, pp. 573–584, 2013. View at: Publisher Site | Google Scholar
  45. P. Angel and A. Szabowski, “Function of AP-1 target genes in mesenchyma lepithelial cross-talk in skin,” Biochemical Pharmacology, vol. 64, no. 5-6, pp. 949–956, 2002. View at: Publisher Site | Google Scholar
  46. M. K. Oyoshi, R. He, L. Kumar, J. Yoon, and R. S. Geha, “Chapter 3 Cellular and Molecular Mechanisms in Atopic Dermatitis,” Adv Immunol, vol. 102, pp. 135–226, 2009. View at: Publisher Site | Google Scholar
  47. F. Liu, D. D. Chen, X. Sun et al., “Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiopoietin-1 in type 2 diabetes,” Diabetes, vol. 63, no. 5, pp. 1763–1778, 2014. View at: Publisher Site | Google Scholar
  48. H. Zhao, S. Lu, J. Chai et al., “Hydrogen sulfide improves diabetic wound healing in ob/ob mice via attenuating inflammation,” Journal of Diabetes and its Complications, vol. 31, no. 9, pp. 1363–1369, 2017. View at: Publisher Site | Google Scholar
  49. A. Papapetropoulos, A. Pyriochou, Z. Altaany et al., “Hydrogen sulfide is an endogenous stimulator of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 51, pp. 21972–21977, 2009. View at: Publisher Site | Google Scholar
  50. S. Saha, P. K. Chakraborty, X. Xiong et al., “Cystathionine β-synthase regulates endothelial function via protein S-sulfhydration,” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, vol. 30, no. 1, pp. 441–456, 2016. View at: Publisher Site | Google Scholar
  51. C.-T. Yang, L. Chen, W. Chen et al., “Hydrogen sulfide primes diabetic wound to close through inhibition of NETosis,” Molecular and Cellular Endocrinology, vol. 480, pp. 74–82, 2019. View at: Publisher Site | Google Scholar
  52. G. Wang and W. Li, “Hydrogen sulfide improves vessel formation of the ischemic adductor muscle and wound healing in diabetic <i>db/db</i> mice,” Iranian Journal of Basic Medical, vol. 22, no. 10, pp. 1192–1197, 2019. View at: Publisher Site | Google Scholar
  53. G. Wang, W. Li, Q. Chen, Y. Jiang, X. Lu, and X. Zhao, “Hydrogen sulfide accelerates wound healing in diabetic rats,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 5, pp. 5097–5104, 2015. View at: Google Scholar
  54. K. M. Venardos, A. Perkins, J. Headrick, and D. M. Kaye, “Myocardial ischemiareperfusion injury, antioxidant enzyme systems, and selenium: a review,” Current Medicinal Chemistry, vol. 14, no. 14, pp. 1539–1549, 2007. View at: Publisher Site | Google Scholar
  55. Y. Kimura and H. Kimura, “Hydrogen sulfide protects neurons from oxidative stress,” Neuroscience Research, vol. 18, no. 10, pp. 1165–1167, 2004. View at: Publisher Site | Google Scholar
  56. B. Geng, L. Chang, C. Pan et al., “Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol,” Biochemical and Biophysical Research Communications, vol. 318, no. 3, pp. 756–763, 2004. View at: Publisher Site | Google Scholar
  57. M. Whiteman, J. S. Armstrong, S. H. Chu et al., “The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite ‘scavenger’?” Journal of Neurochemistry, vol. 90, no. 3, pp. 765–768, 2004. View at: Publisher Site | Google Scholar
  58. A. Slominski, D. J. Tobin, S. Shibahara, and J. Wortsman, “Melanin pigmentation in mammalian skin and its hormonal regulation,” Physiological Reviews, vol. 84, no. 4, pp. 1155–1228, 2004. View at: Publisher Site | Google Scholar
  59. E. K. Nishimura, S. R. Granter, and D. E. Fisher, “Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche,” Science, vol. 307, no. 5710, pp. 720–724, 2005. View at: Publisher Site | Google Scholar
  60. R. M. White and L. I. Zon, “Melanocytes in development, regeneration, and cancer,” Cell Stem Cell, vol. 3, no. 3, pp. 242–252, 2008. View at: Publisher Site | Google Scholar
  61. Y. Yamaguchi, M. Brenner, and V. J. Hearing, “The regulation of skin pigmentation,” The Journal of Biological Chemistry, vol. 282, no. 38, pp. 27557–27561, 2007. View at: Publisher Site | Google Scholar
  62. H. Wu, F. Li, S. Wang et al., “Ceria nanocrystals decorated mesoporous silica nanoparticle based ROS-scavenging tissue adhesive for highly efficient regenerative wound healing,” Biomaterials, vol. 151, no. 4, pp. 66–77, 2018. View at: Publisher Site | Google Scholar
  63. G.-Y. Zhang, L.-C. Wu, T. Dai et al., “NADPH oxidase-2 is a key regulator of human dermal fibroblasts: a potential therapeutic strategy for the treatment of skin fibrosis,” Experimental Dermatology, vol. 23, no. 4, pp. 639–644, 2014. View at: Publisher Site | Google Scholar
  64. H. H. Jeon, Q. Yu, Y. Lu et al., “FOXO1 regulates VEGFA expression and promotes angiogenesis in healing wounds,” The Journal of Pathology, vol. 245, no. 3, pp. 258–264, 2018. View at: Publisher Site | Google Scholar
  65. M. Xu, Y. Hua, Y. Qi, G. Meng, and S. Yang, “Exogenous hydrogen sulphide supplement accelerates skin wound healing via oxidative stress inhibition and vascular endothelial growth factor enhancement,” Experimental Dermatology, vol. 28, no. 7, pp. 776–785, 2019. View at: Publisher Site | Google Scholar
  66. R. Zhuang, L. Guo, J. du, S. Wang, J. Li, and Y. Liu, “Exogenous hydrogen sulfide inhibits oral mucosal wound-induced macrophage activation via the NF-κB pathway,” Oral Diseases, vol. 24, no. 5, pp. 793–801, 2018. View at: Publisher Site | Google Scholar
  67. L. Fang, H. Li, C. Tang, B. Geng, Y. Qi, and X. Liu, “Hydrogen sulfide attenuates the pathogenesis of pulmonary fibrosis induced by bleomycin in rats,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 7, pp. 531–538, 2009. View at: Publisher Site | Google Scholar
  68. G. Tan, S. Pan, J. Li et al., “Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats,” PLoS ONE, vol. 6, no. 10, article e25943, 2011. View at: Publisher Site | Google Scholar
  69. K. Song, F. Wang, Q. Li et al., “Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy,” Kidney International, vol. 85, no. 6, pp. 1318–1329, 2014. View at: Publisher Site | Google Scholar
  70. T. D. Oury, K. Thakker, M. Menache, L. Y. Chang, J. D. Crapo, and B. J. Day, “Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin,” American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 2, pp. 164–169, 2001. View at: Publisher Site | Google Scholar
  71. H. Ming-Ju, H. Yih-Shou, C. Tzy-Yen, and C. Hui-Ling, “Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line,” Journal of Cellular Biochemistry, vol. 112, no. 1, pp. 233–243, 2011. View at: Publisher Site | Google Scholar
  72. J. Kim, Y. M. Seok, K. J. Jung, and K. M. Park, “Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice,” American Journal of Physiology: Renal Physiology, vol. 297, no. 2, pp. F461–F470, 2009. View at: Publisher Site | Google Scholar
  73. R. Sunami, H. Sugiyama, D. H. Wang et al., “Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction,” American Journal of Physiology: Renal Physiology, vol. 286, no. 6, pp. F1030–F1038, 2004. View at: Publisher Site | Google Scholar
  74. F. Talaei, V. M. van Praag, and R. H. Henning, “Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway,” Pharmacological Research, vol. 74, no. 4, pp. 34–44, 2013. View at: Publisher Site | Google Scholar
  75. Z. Wang, X. Yin, L. Gao et al., “The protective effect of hydrogen sulfide on systemic sclerosis associated skin and lung fibrosis in mice model,” Springerplus, vol. 5, no. 1, p. 1084, 2016. View at: Publisher Site | Google Scholar
  76. Z. W. Lee, X. Y. Teo, E. Y. Tay et al., “Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance,” British Journal of Pharmacology, vol. 171, no. 18, pp. 4322–4336, 2014. View at: Publisher Site | Google Scholar
  77. H.-C. Wang, J.-H. Yang, S.-C. Hsieh, and L.-Y. Sheen, “Allyl sulfides inhibit cell growth of skin cancer cells through induction of DNA damage mediated G2/M arrest and apoptosis,” Journal of Agricultural and Food Chemistry, vol. 58, no. 11, pp. 7096–7103, 2010. View at: Publisher Site | Google Scholar
  78. H.-C. Wang, Y.-L. Chu, S.-C. Hsieh, and L.-Y. Sheen, “Diallyl trisulfide inhibits cell migration and invasion of human melanoma a375 cells via inhibiting integrin/facal adhesion kinase pathway,” Environmental Toxicology, vol. 32, no. 11, pp. 2352–2359, 2017. View at: Publisher Site | Google Scholar
  79. G. Ercolano, P. de Cicco, F. Frecentese et al., “Anti-metastatic properties of naproxen-HBTA in a murine model of cutaneous melanoma,” Frontiers in Pharmacology, vol. 10, p. 66, 2019. View at: Publisher Site | Google Scholar
  80. C. Leikam, A. Hufnagel, S. Walz et al., “Cystathionase mediates senescence evasion in melanocytes and melanoma cells,” Oncogene, vol. 33, no. 6, pp. 771–782, 2014. View at: Publisher Site | Google Scholar
  81. A. N. Lin, J. R. Reimer, and D. M. Carte, “Sulfur revisited,” Journal of the American Academy of Dermatology, vol. 18, no. 3, pp. 553–558, 1988. View at: Publisher Site | Google Scholar
  82. S. Valitutti, F. Costellino, and P. Musiani, “Effect of sulphurus thermal water on T lymphocytes proliferative response,” Annals of Allergy, vol. 65, no. 6, pp. 463–468, 1990. View at: Google Scholar
  83. H. Matz, E. Orion, and R. Wolf, “Balneotherapy in dermatology,” Dermatologic Therapy, vol. 16, no. 2, pp. 132–140, 2003. View at: Publisher Site | Google Scholar
  84. S. Cacciapuoti, M. A. Luciano, M. Megna et al., “The role of thermal water in chronic skin diseases management: a review of the literature,” Journal of Clinical Medicine, vol. 9, no. 9, p. 3047, 2020. View at: Publisher Site | Google Scholar
  85. T. Inoue, S. Inoue, and K. Kubata, “Bactericidal activity of manganese and iodide ions against Staphylococcus aureus: a possible treatment for acute atopic dermatitis,” Acta Dermato-Venereologica, vol. 79, no. 5, pp. 360–362, 1999. View at: Publisher Site | Google Scholar
  86. H. Akiyama, O. Yamasaki, J. Tada, K. Kubota, and J. Arata, “Antimicrobial effects of acidic hot-spring water on Staphylococcus aureus strains isolated from atopic dermatitis patients,” Journal of Dermatological Science, vol. 24, no. 2, pp. 112–118, 2000. View at: Publisher Site | Google Scholar
  87. E. Scala, R. di Caprio, S. Cacciapuoti et al., “A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26,” British Journal of Dermatology, vol. 181, no. 5, pp. 1038–1045, 2019. View at: Publisher Site | Google Scholar
  88. H. Gollnick, W. Cunliffe, D. Berson et al., “Management of acne: a report from a global alliance to improve outcomes in acne,” Journal of the American Academy of Dermatology, vol. 49, no. 1, pp. S1–S37, 2003. View at: Publisher Site | Google Scholar
  89. V. Calderone, A. Martelli, L. Testai, V. Citi, and M. C. Breschi, “Using hydrogen sulfide to design and develop drugs,” Expert Opinion on Drug Discovery, vol. 11, no. 2, pp. 163–175, 2016. View at: Publisher Site | Google Scholar
  90. L. Li, M. Whiteman, Y. Y. Guan et al., “Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide,” Circulation, vol. 117, no. 18, pp. 2351–2360, 2008. View at: Publisher Site | Google Scholar
  91. P. de Cicco, E. Panza, G. Ercolano et al., “ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo,” Pharmacological Research, vol. 114, pp. 67–73, 2016. View at: Publisher Site | Google Scholar
  92. J. Wu, Y. Li, C. He et al., “Novel H2S releasing nanofibrous coating for in vivo dermal wound regeneration,” ACS Applied Materials & Interfaces, vol. 8, no. 41, pp. 27474–27481, 2016. View at: Publisher Site | Google Scholar
  93. W. C. Lin, C. C. Huang, S. J. Lin et al., “In situ depot comprising phase-change materials that can sustainably release a gasotransmitter H2S to treat diabetic wounds,” Biomaterials, vol. 145, pp. 1–8, 2017. View at: Publisher Site | Google Scholar
  94. J. Baek and M.-G. Lee, “Oxidative stress and antioxidant strategies in dermatology,” Redox Report, vol. 21, no. 4, pp. 164–169, 2016. View at: Publisher Site | Google Scholar
  95. S. Feng, Y. Zhao, M. Xian, and Q. Wang, “Biological thiols-triggered hydrogen sulfide releasing microfibers for tissue engineering applications,” Acta Biomaterialia, vol. 27, pp. 205–213, 2015. View at: Publisher Site | Google Scholar

Copyright © 2021 Qing Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.